Nicosia, Cyprus, and London, UK, November 8th, 2011

Trojantec Ltd, a privately held drug delivery company and developer of cancer and cancer stem cells therapeutics, announced today a series of successful fundraising efforts.

Trojantec is pleased to announce that it was awarded a "Leonardo Da Vinci" grant in the form of non-dilutive funding by the European Commission. The goal of Leonardo da Vinci Multilateral Projects is to improve the quality and attractiveness of the European research system. It integrates innovative projects into public and/or private companies at the national, local or regional level.

Also, the Company announced the completion of a new equity financing round.The round was led by Jim Mellon a prominent investor, current Trojantec shareholder and now a new director of Trojantec. Mr Mellon is well known for his extensive experience in emerging markets, real estate, mining and biotechnology. He is the author of a book on the biotech industry. His co-investor is Dr Greg Bailey, managing partner at Palantir Group, a company that invests in biotech and technology. He is also a current shareholder and director of Trojantec.

"We are making good progress in advancing our preclinical technology platform and products and this funding will help us to continue our momentum", said Agamemnon Epenetos, Chairman of Trojantec. "We are pleased to have such high quality investors and directors on the Board particularly in light of current market conditions."

Trojantec is a UK and Cyprus based biopharmaceutical Company focused on developing its unique drug delivery platform technology and its first-in-class innovative therapeutics, initially, in Oncology. Trojantec is one of a few Companies in the World developing drugs that not only attack Cancer Cells, but more importantly, destroy Cancer Stem Cells. Through research and development in this novel, exciting field, we wish to achieve the next order of magnitude of efficacy against cancer and cancer stem cells.